RUNX1 promotes liver fibrosis progression through regulating TGF ‐β signalling
International Journal of Experimental Pathology · 2023-08 · 104 (4) · 188-198
DOI: 10.1111/iep.12474 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Experimental Pathology, online erschienen am 17.04.2023. Verfasst von Zhaoyang Guo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Shandong Provincial Hospital, Shandong University, Jinan, China. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Liver Cirrhosis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Postdoctoral Innovation Project of Shandong Province.
Abstract (Originalsprache)
Liver fibrosis is caused by chronic liver injury. There are limited treatments for it, and the pathogenesis is unclear. Therefore, there is an urgent need to explore the pathogenesis of liver fibrosis, and to try to identify new potential therapeutic targets. For this study we used the carbon tetrachloride abdominal injection induced liver fibrosis animal model in mice. Primary hepatic stellate cell isolation was performed by a density‐gradient separation method, and this was followed by immunofluorescence stain analyses. Signal pathway analysis was performed by dual‐luciferase reporter assay and western blotting. Our results showed that RUNX1 was upregulated in cirrhotic liver tissues compared with normal liver tissues. Besides, overexpression of RUNX1 caused more severe liver fibrosis lesions than control group under CCl 4 ‐induced conditions. Moreover, α‐SMA expression in the RUNX1 overexpression group was significantly higher than in the control group. Interestingly, we found that RUNX1 could promote the activation of TGF‐β/Smads in a dual‐luciferase reporter assay. Thus we demonstrated that RUNX1 could be considered as a new regulator of hepatic fibrosis by activating TGF‐β/Smads signalling. Based on this, we concluded that RUNX1 may be developed as a new therapeutic target in the treatment of liver fibrosis in the future. In addition, this study also provides a new insight about the aetiology of liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Shandong Provincial Hospital, Shandong University, Jinan, China.
- Department of Infectious Diseases, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Department of Digestive Endoscopy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- School of Basic Medical Sciences, Cheeloo Medical College, Shandong University, Jinan, Shandong, China.
ORCID-Profile: Wanhua Ren
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Postdoctoral Innovation Project of Shandong Province
- Jinan Clinical Medical Science and Technology Innovation Plan
Zitieren
APA
Guo, Z., Liu, X., Zhao, S., Sun, F., Ren, W., & Ma, M. (2023). RUNX1 promotes liver fibrosis progression through regulating TGF ‐β signalling. International Journal of Experimental Pathology, 104(4), 188-198. https://doi.org/10.1111/iep.12474
Vancouver
Guo Z, Liu X, Zhao S, Sun F, Ren W, Ma M. RUNX1 promotes liver fibrosis progression through regulating TGF ‐β signalling. International Journal of Experimental Pathology. 2023;104(4):188-198. doi:10.1111/iep.12474
BibTeX
@article{Guo2023,
author = {Guo, Zhaoyang and Liu, Xinxin and Zhao, Shulei and Sun, Fengkai and Ren, Wanhua and Ma, Mingze},
title = {RUNX1 promotes liver fibrosis progression through regulating TGF ‐β signalling},
journal = {International Journal of Experimental Pathology},
year = {2023},
volume = {104},
number = {4},
pages = {188--198},
doi = {10.1111/iep.12474}
}
EUVIMED